R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

Juan Montoro; Giovanna Andreola; Angelo Gardellini; Aleksandra Babic; Mara Negri; Niccolò Frungillo; Giovanni Martinelli; Daniele Laszlo

doi:10.1016/j.transci.2014.03.006

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

Juan Montoro, Giovanna Andreola, Angelo Gardellini, Aleksandra Babic, Mara Negri, Niccolò Frungillo, Giovanni Martinelli, Daniele Laszlo

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×10⁶ CD34+cells/kg, 80% of them at least 5×10⁶ CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.

Original language	English
Pages (from-to)	411-414
Number of pages	4
Journal	Transfusion and Apheresis Science
Volume	50
Issue number	3
DOIs	https://doi.org/10.1016/j.transci.2014.03.006
Publication status	Published - 2014

Keywords

CD34+ collection
Diffuse large B-cell lymphoma
Pegfilgrastim
R-ESHAP
Stem cell mobilization

ASJC Scopus subject areas

Hematology
Medicine(all)

Access to Document

10.1016/j.transci.2014.03.006

Cite this

Montoro, J., Andreola, G., Gardellini, A., Babic, A., Negri, M., Frungillo, N., Martinelli, G., & Laszlo, D. (2014). R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. Transfusion and Apheresis Science, 50(3), 411-414. https://doi.org/10.1016/j.transci.2014.03.006

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. / Montoro, Juan; Andreola, Giovanna; Gardellini, Angelo; Babic, Aleksandra; Negri, Mara; Frungillo, Niccolò; Martinelli, Giovanni; Laszlo, Daniele.

In: Transfusion and Apheresis Science, Vol. 50, No. 3, 2014, p. 411-414.

Research output: Contribution to journal › Article › peer-review

Montoro, J, Andreola, G, Gardellini, A, Babic, A, Negri, M, Frungillo, N, Martinelli, G & Laszlo, D 2014, 'R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma', Transfusion and Apheresis Science, vol. 50, no. 3, pp. 411-414. https://doi.org/10.1016/j.transci.2014.03.006

Montoro, Juan ; Andreola, Giovanna ; Gardellini, Angelo ; Babic, Aleksandra ; Negri, Mara ; Frungillo, Niccolò ; Martinelli, Giovanni ; Laszlo, Daniele. / R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. In: Transfusion and Apheresis Science. 2014 ; Vol. 50, No. 3. pp. 411-414.

@article{1683c34ffc324b6ab59aa47dffbc329c,

title = "R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma",

abstract = "Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×106 CD34+cells/kg, 80% of them at least 5×106 CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.",

keywords = "CD34+ collection, Diffuse large B-cell lymphoma, Pegfilgrastim, R-ESHAP, Stem cell mobilization",

author = "Juan Montoro and Giovanna Andreola and Angelo Gardellini and Aleksandra Babic and Mara Negri and Niccol{\`o} Frungillo and Giovanni Martinelli and Daniele Laszlo",

year = "2014",

doi = "10.1016/j.transci.2014.03.006",

language = "English",

volume = "50",

pages = "411--414",

journal = "Transfusion and Apheresis Science",

issn = "1473-0502",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

AU - Montoro, Juan

AU - Andreola, Giovanna

AU - Gardellini, Angelo

AU - Babic, Aleksandra

AU - Negri, Mara

AU - Frungillo, Niccolò

AU - Martinelli, Giovanni

AU - Laszlo, Daniele

PY - 2014

Y1 - 2014

N2 - Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×106 CD34+cells/kg, 80% of them at least 5×106 CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.

AB - Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma.We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ≥2×106 CD34+cells/kg, 80% of them at least 5×106 CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.

KW - CD34+ collection

KW - Diffuse large B-cell lymphoma

KW - Pegfilgrastim

KW - R-ESHAP

KW - Stem cell mobilization

UR - http://www.scopus.com/inward/record.url?scp=84926119861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926119861&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2014.03.006

DO - 10.1016/j.transci.2014.03.006

M3 - Article

C2 - 24751603

AN - SCOPUS:84926119861

VL - 50

SP - 411

EP - 414

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -

R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this